Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus
Kuznik BI, Isakova NV, Kliuchereva NN, Maleeva NV, Pinelis IS · 2007 · Advances in gerontology = Uspekhi gerontologii 20(2):106-115. PMID 18306698
What does this source report?
Reports immune and coagulation changes during adjunctive Vilon treatment.
- Population and setting
- Type-1 diabetes patients receiving adjunctive care
- Evidence type
- Uncontrolled human report
- Preparation
- Synthetic peptide / defined-sequence research
- Source language
- English abstract; see original for language
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Enrollment and allocation are not established by the abstract; do not infer an insulin-replacement treatment.
- Full methods, adverse-event reporting and independent replication remain to be appraised.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Europe PMC indexed citation and abstract checked. Full original paper not reviewed.
Recorded source-check date: 2026-09-30. This date does not imply a completed systematic review.
Source provenance: Journal publication
Cite and trace this record
Original source: Kuznik BI, Isakova NV, Kliuchereva NN, Maleeva NV, Pinelis IS. Effect of vilon on the immunity status and coagulation hemostasis in patients of different age with diabetes mellitus Advances in gerontology = Uspekhi gerontologii 20(2):106-115. PMID 18306698 2007.
Molekul research summary: https://molekul.io/research/kh-18306698. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry